Confronting multidrug-resistant Acinetobacter baumannii: a review

Neonakis, Ioannis K.; Spandidos, Demetrios Α.; Petinaki, Efthimia

doi:10.1016/j.ijantimicag.2010.10.014

Cited by 106 publications

(75 citation statements)

References 138 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, rifampicin has been proposed as an alternative antimicrobial agent for the treatment of MDR A. baumannii, based on outcomes of in vitro studies 2,7,8 and in vivo infection models 12,27 . A previous study has shown that 64% of MDR A. baumannii were susceptible to rifampicin 7 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Antimicrobial susceptibility of Acinetobacter baumannii isolated from hospital patients

Tunyapanit¹,

Pruekprasert²,

Laoprasopwattana³

et al. 2014

ScienceAsia

View full text Add to dashboard Cite

ABSTRACT:The incidence of multidrug-resistant Acinetobacter baumannii (MDR A. baumannii) is increasing worldwide and is leading to therapeutic problems. We investigated the in vitro activities of cefoperazone/sulbactam, colistin, imipenem, and rifampicin alone and in double combinations against 100 A. baumannii isolates from patients at Songklanagarind Hospital in Songkhla Province, Thailand. The E-test method was used to determine antimicrobial susceptibility, the minimal inhibitory concentration (MIC) and for antimicrobial combination testing. A. baumannii isolates were susceptible to colistin (97%), cefoperazone/sulbactam (69%), imipenem (45%), and rifampicin (13%). Fifty-nine percent of them were MDR A. baumannii. Colistin was superior to cefoperazone/sulbactam, rifampicin and imipenem against MDR A. baumannii and the MIC50, MIC90 of colistin were 0.75 and 1 µg/ml, respectively. Non-MDR A. baumannii isolates were susceptible to cefoperazone/sulbactam (100%), colistin (95%), imipenem (93%) and rifampicin (2%). Combinations of cefoperazone/sulbactam plus colistin or rifampicin, imipenem plus colistin or rifampicin and colistin plus rifampicin showed indifferent effects against most MDR isolates. Of all the antimicrobial combinations tested, cefoperazone/sulbactam plus rifampicin produced the highest percentages (42%) of synergy, partial synergy, and additive results. The activity rate of cefoperazone/sulbactam against MDR A. baumannii was higher when combined with rifampicin than colistin. Thus colistin had the greatest activity against most MDR and non-MDR A. baumannii isolates among all of the antibiotics tested. Cefoperazone/sulbactam and imipenem showed good activity against non-MDR isolates, and cefoperazone/sulbactam combined with rifampicin may be useful in treating infections caused by MDR isolates.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Infections caused by MDR A. baumannii are associated with high morbidity rates, especially in immunocompromised patients, patients admitted to intensive care units, and patients treated www.scienceasia.org with broad-spectrum antibiotics 1,2 .…”

Section: Introductionmentioning

confidence: 99%

Antimicrobial susceptibility of Acinetobacter baumannii isolated from hospital patients

Tunyapanit¹,

Pruekprasert²,

Laoprasopwattana³

et al. 2014

ScienceAsia

View full text Add to dashboard Cite

show abstract

“…It can survive for longer periods in hospital settings and is potentially capable of causing serious hospital outbreaks. Over the last 10 years, the clinical significance of A. baumannii has increased through its ability to acquire multi-drug resistance and so reduce therapeutic options [2]. In most hospital settings, it is increasingly associated with nosocomial pneumonia in intensive care units, particularly in patients with ventilator-associated pneumonia [3,4].…”

Section: Introductionmentioning

confidence: 99%

Genotyping methods for monitoring the epidemic evolution of A. baumannii strains

Ahmed

Alp

2015

J Infect Dev Ctries

View full text Add to dashboard Cite

Acinetobacter baumannii is clustered with other phenotypically similar species into what has commonly become known as the ACB complex: A. calcoaceticus, A. pittii and, A. nosocomialis. The ecology and pathology of most of these species are not well understood, mainly because current specific phenotypic techniques have, to date, been insufficient. This has inhibited both the precise identification of, as well as the ability to discriminate between, these clinically important and closely related Acinetobacter strains. However, new genotypic methods have greatly enhanced our capacity to identify the ACB complex. This has resulted in the implementation of more rational infection control programs. Several genotypic identification methods are explored in this study, including non-polymerase chain reaction (PCR)-based and PCR-based methods. These methods include ribotyping, pulsed-field gel electrophoresis, 16S rRNA identification, multilocus sequence typing, single locus sequence typing, restriction fragment length polymorphism analysis, restriction analysis of 16S-23S rRNA intergenic spacer sequences, rapid amplification of polymorphic DNA, and repetitive extragenic palindromic PCR; however, there is no current single ideal genotyping method. Each one has its own advantages and disadvantages. With this in mind we reviewed current and new genotyping methods used to characterize the Acinetobacter species.

show abstract

“…and Morganella spp. 22,38,54,55 However, evidence of increased mortality, compared to other antibiotic therapies, especially in ventilator-associated pneumonia 48 leads to caution in its use. Moreover, a serious drawback, at least for monotherapy in bacteremia, is the low serum level obtained.…”

mentioning

confidence: 99%

“…2,31,81,82 Many authors argue that rifampin should be considered for addition to other active antibiotics in the treatment of uncontrolled infection due to MDR bacteria, 31,55,78,[83][84][85] though there is little evidence of why rifampicin should improve outcome and no randomized trials to show that it does improve these outcomes. Further obstacles include: (a) there is no relevant in vitro breakpoint for susceptibility to rifampin against Gram-negative bacteria; (b) toxic potential of rifampin; (c) multitude of drug interactions between rifampin and other agents, a main concern especially in onco-hematological patients and allogeneic HSCT recipients who receive a lot of other drugs concomitantly (such as cyclosporine, mycophenolate mofetil, antifungals, antivirals).…”

mentioning

confidence: 99%

Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011)

et al. 2013

View full text Add to dashboard Cite

The detection of multi-resistant bacterial pathogens, particularly those to carbapenemases, in leukemic and stem cell transplant patients forces the use of old or non-conventional agents as the only remaining treatment options. These include colistin/polymyxin B, tigecycline, fosfomycin and various anti-gram-positive agents. Data on the use of these agents in leukemic patients are scanty, with only linezolid subjected to formal trials. The Expert Group of the 4 th European Conference on Infections in Leukemia has developed guidelines for their use in these patient populations. Targeted therapy should be based on (i) in vitro susceptibility data, (ii) knowledge of the best treatment option against the particular species or phenotype of bacteria, (iii) pharmacokinetic/pharmacodynamic data, and (iv) careful assessment of the risk-benefit balance. For infections due to resistant Gram-negative bacteria, these agents should be preferably used in combination with other agents that remain active in vitro, because of suboptimal efficacy (e.g., tigecycline) and the risk of emergent resistance (e.g., fosfomycin). The paucity of new antibacterial drugs in the near future should lead us to limit the use of these drugs to situations where no alternative exists. ABSTRACT © F e r r a t a S t o r t i F o u n d a t i o n 2 0 1 3organizing committee and experts were solicited to form the working group. The group reviewed the published English-language literature and prepared proposals on treatment options for infections due to resistant bacteria. Papers for review were sought using PubMed with the terms "linezolid", "daptomycin", "quinupristin/ dalfopristin", "colistin or polymyxin", "tigecycline", "fosfomycin", "telavancin", "ceftaroline" AND "stem cell transplantation or bone marrow transplant or leukemia or hematological malignancy or cancer". References cited in the articles identified were also considered. In respect of 'Duration of therapy', the main search terms used were "antibiotic therapy"; "stem cell transplantation or bone marrow transplantation or hematological malignancy or cancer"; "febrile neutropenia" and "duration therapy", "discontinuation antibiotics" and "microbiologically documented infection". Definitions of resistanceA bacterial isolate was considered non-susceptible if it was categorized resistant, intermediate or non-susceptible when using clinical breakpoints of the European Committee on Antimicrobial Susceptibility Testing (EUCAST), Clinical and Laboratory Standards Institute (CLSI) or the US Food and Drug Administration (FDA). Definitions of 'MDR' vary among authors and usually presume resistance to at least two antibiotics used in empiric therapy (3 rd 4 th -generation cephalosporins, carbapenems or piperacillin/tazobactam) or resistance to at least three of the following antibiotic classes: antipseudomonal penicillins, cephalosporins, carbapenems, aminoglycosides and fluoroquinolones. [11][12][13][14][15] According to the recent definition of the European Centre for Disease Prevention and Control...

show abstract

Confronting multidrug-resistant Acinetobacter baumannii: a review

Cited by 106 publications

References 138 publications

Antimicrobial susceptibility of Acinetobacter baumannii isolated from hospital patients

Antimicrobial susceptibility of Acinetobacter baumannii isolated from hospital patients

Genotyping methods for monitoring the epidemic evolution of A. baumannii strains

Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011)

Contact Info

Product

Resources

About